Erosive gastritis was found during endoscopic evaluation in patient taking for two months indometacine for treatment of rheumatoid arthritis. Physician has decided to discontinue NSAID indometacine and to administer more safe anti-inflammatory drug. Which preparation has been administered to the patient?
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
The textbook sources confirm the answer clearly. Here is a full explanation:
Answer: Celecoxib (a selective COX-2 inhibitor)
Why indomethacin caused the problem
Indomethacin is a non-selective NSAID - it blocks both COX-1 and COX-2 isoenzymes. COX-1 is constitutively expressed in the gastric mucosa and is responsible for producing cytoprotective prostaglandins (PGE2, PGI2) that:
- Stimulate mucus and bicarbonate secretion
- Maintain mucosal blood flow
- Promote epithelial cell renewal
Blocking COX-1 removes this mucosal "shield," leading to erosions and ulcers - exactly what was found on endoscopy.
What makes celecoxib safer
Celecoxib selectively inhibits COX-2 only:
- COX-2 is the inducible isoform upregulated at sites of inflammation (joints, synovium) - responsible for the prostaglandins that cause pain and swelling in rheumatoid arthritis
- By sparing COX-1, celecoxib preserves gastric mucosal prostaglandin synthesis, leaving the gut's protective mechanisms intact
- Studies show COX-2-selective inhibitors produce gastric/duodenal mucosal injury comparable to placebo, making them far safer for patients with a history of GI problems
As stated in Harrison's Principles of Internal Medicine 22E: "The highly selective COX-2 inhibitors, celecoxib and rofecoxib, are 100 times more selective inhibitors of COX-2 than standard NSAIDs, leading to gastric or duodenal mucosal injury that is comparable to placebo."
And from Katzung's Basic and Clinical Pharmacology, 16th Ed: "The selective COX-2 inhibitors do not affect platelet function at their usual doses. The in vivo efficacy of COX-2-selective drugs equals that of the older NSAIDs, while GI safety may be improved."
Important caveats
| Consideration | Detail |
|---|---|
| CV risk | Celecoxib carries increased risk of MI and stroke - caution in patients with cardiovascular disease |
| Aspirin co-use | Taking low-dose aspirin alongside celecoxib eliminates most of the GI benefit |
| Anti-inflammatory efficacy | Equal to non-selective NSAIDs for rheumatoid arthritis management |
| Other options | Naproxen + PPI or misoprostol is an alternative if celecoxib is contraindicated |
Summary
The physician switched from indomethacin (non-selective COX-1/COX-2 inhibitor) to celecoxib (selective COX-2 inhibitor) - maintaining effective anti-inflammatory treatment for the patient's rheumatoid arthritis while protecting the gastric mucosa from further damage.
This is a shared conversation. Sign in to Orris to start your own chat.